HELP.NE
Cybin D/B/A Helus Pharma
Cboe CACADEQUITY
DELAYED
Last price
17.41
▲ 0.31 (1.81%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
17.30
Prev close
17.10
Day high
17.75
Day low
17.25
Volume
13.15K
Market cap
—
P/E (TTM)
—
52W range
5.30 – 17.75
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+4.82%
+6.2%
1M
+57.70%
+54.0%
3M
+167.02%
+163.9%
6M
+86.20%
+75.1%
YTD
+56.71%
+44.4%
1Y
+89.03%
+69.0%
3Y
+4.13%
-70.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Cost of revenue | — | — | — | — | $0 | — |
| Gross profit | — | — | — | — | $0 | — |
| Research & development | $86.59M | $39.21M | $32.36M | $25.49M | — | +120.8% |
| Selling, general & admin | $56.00M | $63.91M | $46.47M | $26.03M | — | -12.4% |
| Total operating expense | $142.59M | $103.13M | $78.84M | $51.52M | — | +38.3% |
| Operating income | -$142.59M | -$103.13M | -$78.84M | -$51.52M | — | -38.3% |
| Net interest income | $2.18M | $5.99M | $619.00K | $603.00K | — | -63.6% |
| Pre-tax income | -$148.00M | -$81.59M | -$78.08M | -$47.49M | — | -81.4% |
| Net income | -$148.00M | -$81.61M | -$78.08M | -$47.49M | — | -81.4% |
| Net income to common | -$148.00M | -$81.61M | -$78.08M | -$47.49M | — | -81.4% |
| Basic EPS | -4.25 | -4.04 | -6.96 | -9.88 | — | -5.2% |
| Diluted EPS | -4.25 | -4.04 | -6.96 | -9.88 | — | -5.2% |
| EBIT | -$142.59M | -$103.13M | -$78.84M | -$51.52M | — | -38.3% |
| EBITDA | -$142.47M | -$102.78M | -$78.41M | -$51.27M | — | -38.6% |
| Basic shares | 34.80M | 20.22M | 8.30M | 4.88M | — | +72.1% |
| Diluted shares | 34.80M | 20.22M | 8.30M | 4.88M | — | +72.1% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $157.26M | $93.92M | $208.99M | $16.63M | +67.4% |
| Cash & short-term investments | $157.26M | $93.92M | $208.99M | $16.63M | +67.4% |
| Accounts receivable | $5.03M | $4.09M | $4.48M | $3.05M | +22.8% |
| Total current assets | $184.52M | $115.45M | $218.54M | $23.18M | +59.8% |
| Property, plant & equipment | $195.00K | $98.00K | $547.00K | $450.00K | +99.0% |
| Goodwill & intangibles | $66.45M | $64.35M | $82.94M | $30.26M | +3.3% |
| Total assets | $251.17M | $179.90M | $302.02M | $53.90M | +39.6% |
| Total current liabilities | $19.38M | $14.90M | $10.10M | $5.66M | +30.0% |
| Total debt | — | $0 | $291.00K | — | — |
| Total liabilities | $19.38M | $14.90M | $10.10M | $5.66M | +30.0% |
| Retained earnings | -$389.54M | -$255.39M | -$226.23M | -$148.15M | -52.5% |
| Shareholder equity | $231.79M | $165.00M | $291.93M | $48.23M | +40.5% |
| Working capital | $165.15M | $100.55M | $208.44M | $17.52M | +64.2% |
| Net tangible assets | $165.34M | $100.65M | $208.99M | $17.97M | +64.3% |
| Shares issued | 51.63M | 21.61M | 20.00M | 5.15M | +138.9% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$148.00M | -$81.61M | -$78.08M | -$47.49M | -81.4% |
| Depreciation & amortisation | $120.00K | $348.00K | $424.00K | $251.00K | -65.5% |
| Stock-based compensation | $10.86M | $31.28M | $13.89M | $4.69M | -65.3% |
| Change in working capital | -$1.26M | -$6.82M | -$5.03M | -$1.44M | +81.6% |
| Operating cash flow | -$133.27M | -$72.33M | -$68.91M | -$47.43M | -84.3% |
| Capital expenditure | -$1.37M | -$1.40M | -$710.00K | -$3.31M | +1.6% |
| Investing cash flow | -$1.36M | -$1.40M | $6.92M | -$3.31M | +2.4% |
| Financing cash flow | $198.24M | $14.10M | $254.51M | $13.56M | +1,306.4% |
| Free cash flow | -$134.64M | -$73.72M | -$69.62M | -$50.74M | -82.6% |
| End cash position | $157.26M | $93.92M | $208.99M | $16.63M | +67.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $28.89M | $23.86M | $18.85M | $14.99M | $18.97M | — | +21.1% |
| Selling, general & admin | $18.97M | $17.35M | $10.04M | $9.63M | $14.30M | — | +9.3% |
| Total operating expense | $47.86M | $41.21M | $28.89M | $24.62M | $33.27M | — | +16.1% |
| Operating income | -$47.86M | -$41.21M | -$28.89M | -$24.62M | -$33.27M | — | -16.1% |
| Net interest income | $1.58M | $1.50M | $1.06M | -$1.96M | $1.44M | — | +5.1% |
| Pre-tax income | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -$30.58M | — | -10.1% |
| Net income | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -$30.58M | — | -10.1% |
| Net income to common | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -$30.58M | — | -10.1% |
| Basic EPS | — | -1.00 | -1.39 | -1.10 | — | -0.38 | — |
| Diluted EPS | — | -1.00 | -1.39 | -1.10 | — | -0.38 | — |
| EBIT | -$47.86M | -$41.21M | -$28.89M | -$24.62M | -$33.27M | — | -16.1% |
| EBITDA | -$47.83M | -$41.19M | -$28.86M | -$24.59M | -$33.21M | — | -16.1% |
| Basic shares | — | 42.52M | 24.21M | 22.40M | — | 20.00M | — |
| Diluted shares | — | 42.52M | 24.21M | 22.40M | — | 20.00M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $157.26M | $195.13M | $83.75M | $118.69M | $93.92M | — | -19.4% |
| Cash & short-term investments | $157.26M | $195.13M | $83.75M | $118.69M | $93.92M | — | -19.4% |
| Accounts receivable | $5.03M | $4.77M | $4.74M | $4.11M | $4.09M | — | +5.5% |
| Total current assets | $184.52M | $222.90M | $114.58M | $143.65M | $115.45M | — | -17.2% |
| Property, plant & equipment | $195.00K | $186.00K | $125.00K | $82.00K | $98.00K | — | +4.8% |
| Goodwill & intangibles | $66.45M | $67.03M | $66.54M | $67.08M | $64.35M | — | -0.9% |
| Total assets | $251.17M | $290.11M | $181.25M | $210.81M | $179.90M | — | -13.4% |
| Total current liabilities | $19.38M | $16.18M | $13.36M | $14.55M | $14.90M | — | +19.8% |
| Long-term debt | — | — | $28.89M | $44.50M | — | — | — |
| Total debt | — | — | $28.89M | $44.50M | $0 | $0 | — |
| Total liabilities | $19.38M | $16.18M | $42.25M | $59.05M | $14.90M | — | +19.8% |
| Retained earnings | -$389.54M | -$342.54M | -$299.87M | -$266.15M | -$255.39M | — | -13.7% |
| Shareholder equity | $231.79M | $273.93M | $139.00M | $151.76M | $165.00M | — | -15.4% |
| Working capital | $165.15M | $206.72M | $101.22M | $129.10M | $100.55M | — | -20.1% |
| Net tangible assets | $165.34M | $206.90M | $72.46M | $84.68M | $100.65M | — | -20.1% |
| Shares issued | 51.63M | 49.89M | 26.10M | 23.03M | 21.61M | — | +3.5% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -$30.58M | -10.1% |
| Depreciation & amortisation | $31.00K | $22.00K | $29.00K | $38.00K | $62.00K | +40.9% |
| Stock-based compensation | $5.26M | $4.48M | $377.00K | $753.00K | $2.09M | +17.4% |
| Change in working capital | $3.70M | $5.88M | -$7.06M | -$3.77M | $8.56M | -37.0% |
| Operating cash flow | -$37.29M | -$31.95M | -$34.48M | -$29.55M | -$21.11M | -16.7% |
| Capital expenditure | -$323.00K | -$383.00K | -$436.00K | -$231.00K | -$1.08M | +15.7% |
| Investing cash flow | -$323.00K | -$383.00K | -$436.00K | -$221.00K | -$1.08M | +15.7% |
| Financing cash flow | -$169.00K | $143.75M | $27.00K | $54.63M | $20.98M | -100.1% |
| Free cash flow | -$37.61M | -$32.33M | -$34.92M | -$29.78M | -$22.20M | -16.3% |
| End cash position | $157.26M | $195.13M | $83.75M | $118.69M | $135.02M | -19.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
15.96
+9.07% from price
SMA 20
14.24
+22.22% from price
SMA 50
10.80
+61.25% from price
SMA 100
8.82
+97.44% from price
SMA 200
8.89
+95.84% from price
EMA 12
15.70
+10.92% from price
EMA 26
13.85
+25.72% from price
EMA 50
11.86
+46.84% from price
RSI (14)
73.4
Overbought
MACD (12,26,9)
1.85
Hist 0.12
ATR (14)
1.23
7.05% of price
Realised vol 30D
97.4%
Annualised
Bollinger upper
18.97
20, 2σ
Bollinger lower
9.52
20, 2σ
50 / 200 cross
Golden
10.80 vs 8.89
Trend bias
Above 200
+95.84%
Risk profile
Beta vs SPY
1.84
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
97.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-54.3%
Peak to trough
Max drawdown 5Y
-95.9%
Peak to trough
ATR 14
1.23
7.05% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Solana Is Beating Ethereum in Tokenized Assets. That Might Not Make It the Better Buy.
Motley Fool · 5m ago
Another travel company shuts down and cancels all trips, refunds available
TheStreet · 6m ago
How Your Social Security Benefit Is Actually Calculated
Motley Fool · 6m ago
Pegula dethrones Swiatek to reach Cincinnati final
AFP · 7m ago
Canada to impose retaliatory tariffs on US steel, electronics, other products, Carney says
Reuters · 9m ago
Quantum Computing vs. Red Cat: Which High-Growth Innovation Stock Is a Better Buy in 2026?
Motley Fool · 10m ago
IPO Fever Heats Up for OpenAI and Anthropic
Motley Fool · 13m ago
Senators Plan a Clarity Act Vote on Sept. 15. What Happens Next for Crypto?
Motley Fool · 31m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.